Search
Skip to Search Results- 10Vaccinia virus
- 6Immunotherapy
- 4Oncolytic virus
- 3Recombination
- 2Breast cancer
- 2Ribonucleotide reductase
- 1Chaurasiya, Shyambabu
- 1Crosley, Powel
- 1Gammon, Donald Brad
- 1Gupta, Nancy
- 1Molavi, Ommoleila
- 1Moussa, Eman W
-
Investigating Radiation in Combination with Oncolytic Vaccinia Virus to Improve the Treatment of Glioblastoma
DownloadFall 2023
Glioblastoma (GBM) is a malignant and immune-suppressed brain cancer that remains incurable despite the current standard of care. Radiotherapy is a mainstay of GBM treatment, however invasive cancer cells outside the irradiated field and radioresistance preclude complete eradication of GBM cells....
-
Measuring proteomic changes associated with viral infections and neurodegenerative diseases using mass spectrometry
DownloadFall 2023
Viral infection and the resultant cellular stress can trigger significant changes to the cellular host proteome. Viral proteases essential to viral replication have been shown to cleave human host protein substrates as a mechanism of immune response evasion. The severe acute respiratory syndrome...
-
Spring 2021
Vaccinia virus (VACV) has shown promise as an oncolytic agent for treating a variety of tumour types, with preliminary results suggesting that this strategy holds promise for treating breast cancer. Our lab has previously modified VACV by deleting virally-encoded enzymes responsible for dNTP...
-
Fall 2021
Poxviruses encode many genes that are orthologs of cellular genes. These orthologs serve many functions, but those that are of most interest are ones that have evolved further and now serve an immune-evasion function. Such genes were likely first acquired by poxviruses through some form of...
-
Spring 2017
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), continues to be a leading infectious cause of death worldwide with approximately 10 million new cases and 2 million deaths attributed annually. There has been resurgence in active TB infections since 1980s and the World Health...
-
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder Cancer
DownloadFall 2017
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
-
Spring 2016
Poxviruses, such as vaccinia virus (VACV) and myxoma virus (MYXV), actively modulate various cellular structures and functions to ensure effective replication and transmission. In the contrary, cells use several restriction mechanisms to mitigate these viruses. This evolutionary relationship is...
-
Fall 2016
Breast cancer (BrCa) is the most common cancer and the leading cause of cancer-related deaths in women worldwide. Current therapies for BrCa are insufficient to cure metastatic disease and are often associated with debilitating side effects that severely deteriorate the quality of patients’...
-
Fall 2014
Smallpox was eradicated using vaccinia viruses (VACV) as vaccines, including Dryvax, a calf-lymph vaccine derived from the New York City Board of Health (NYCBH) strain, and TianTan, a chicken egg cultured vaccine used exclusively in China. To take advantage of the next generation sequencing...